A new mechanism of action of sulodexide in diabetic nephropathy: Inhibits heparanase-1 and prevents FGF-2-induced renal epithelial-mesenchymal transition

Journal of Translational Medicine

Volumn 10, Issue 1, 2012, Pages

  Masola, Valentina ^a   Onisto, Maurizio ^a   Zaza, Gianluigi ^b   Lupo, Antonio ^b   Gambaro, Giovanni ^c  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

^c FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

Author keywords

Diabetic nephropathy; Epithelial mesenchymal transition; Fibrosis; Heparanase 1; Sulodexide; Tubular cells

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; FIBROBLAST GROWTH FACTOR 2; FIBRONECTIN; GELATINASE B; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HEPARANASE; HEPARANASE 1; HEPARIN; SULODEXIDE; UNCLASSIFIED DRUG; VIMENTIN;

ARTICLE; AUTOCRINE EFFECT; CELL MIGRATION; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DRUG EFFICACY; DRUG MECHANISM; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; KIDNEY TUBULE CELL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ZYMOGRAPHY;

BIOLOGICAL MARKERS; CELL LINE; CELL MOVEMENT; DIABETIC NEPHROPATHIES; EPITHELIAL-MESENCHYMAL TRANSITION; FIBROBLAST GROWTH FACTOR 2; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GLUCURONIDASE; GLYCOSAMINOGLYCANS; HUMANS; KIDNEY; MATRIX METALLOPROTEINASE 9; MESODERM; SYNDECAN-1;

EID: 84867669140     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-10-213     Document Type: Article

References (27)

1. Hewitson TD. Renal tubulointerstitial fibrosis: common but never simple. Am J Physiol Renal Physiol 2009, 296(6):F1239-F1244. 10.1152/ajprenal.90521.2008, 19144691.
2. Atkins RC, Zimmet P, . 2010 International Society of Nephrology/International Federation of Kidney Foundations World Kidney Day Steering Committee (RA), International Diabetes Federation (PZ) Diabetic kidney disease: act now or pay later. J Bras Nefrol 2010, 32(1):7-10. 2010 International Society of Nephrology/International Federation of Kidney Foundations World Kidney Day Steering Committee (RA), International Diabetes Federation (PZ).
3. Nath KA. The tubulointerstitium in progressive renal disease. Kidney Int 1998, 54(3):992-994. 10.1046/j.1523-1755.1998.00079.x, 9734628.
4. Liu Y. New insights into epithelial-mesenchymal transition in kidney fibrosis. J Am Soc Nephrol 2010, 21(2):212-222. 10.1681/ASN.2008121226, 20019167.
5. Strutz FM. EMT and proteinuria as progression factors. Kidney Int 2009, 75(5):475-481. 10.1038/ki.2008.425, 18716603.
6. Lan HY. Tubular epithelial-myofibroblast transdifferentiation mechanisms in proximal tubule cells. Curr Opin Nephrol Hypertens 2003, 12(1):25-29. 10.1097/00041552-200301000-00005, 12496662.
7. Burns WC, Twigg SM, Forbes JM, Pete J, Tikellis C, Thallas-Bonke V, Thomas MC, Cooper ME, Kantharidis P. Connective tissue growth factor plays an important role in advanced glycation end product-induced tubular epithelial-to-mesenchymal transition: implications for diabetic renal disease. J Am Soc Nephrol 2006, 17(9):2484-2494. 10.1681/ASN.2006050525, 16914537.
8. Ha H, Lee HB. Reactive oxygen species and matrix remodeling in diabetic kidney. J Am Soc Nephrol 2003, 14(8 Suppl 3):S246-S249.
9. Strutz F, Zeisberg M, Ziyadeh FN, Yang CQ, Kalluri R, Muller GA, Neilson EG. Role of basic fibroblast growth factor-2 in epithelial-mesenchymal transformation. Kidney Int 2002, 61(5):1714-1728. 10.1046/j.1523-1755.2002.00333.x, 11967021.
10. Masola V, Gambaro G, Tibaldi E, Brunati AM, Gastaldello A, D'Angelo A, Onisto M, Lupo A. Heparanase and syndecan-1 interplay orchestrates fibroblast growth factor-2-induced epithelial-mesenchymal transition in renal tubular cells. J Biol Chem 2012, 287(2):1478-1488. 10.1074/jbc.M111.279836, 3256891, 22102278.
11. Ilan N, Elkin M, Vlodavsky I. Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis. Int J Biochem Cell Biol 2006, 38(12):2018-2039. 10.1016/j.biocel.2006.06.004, 16901744.
12. Masola V, Maran C, Tassone E, Zin A, Rosolen A, Onisto M. Heparanase activity in alveolar and embryonal rhabdomyosarcoma: implications for tumor invasion. BMC Cancer 2009, 9:304. 10.1186/1471-2407-9-304, 2743710, 19715595.
13. Masola V, Gambaro G, Tibaldi E, Onisto M, Abaterusso C, Lupo A. Regulation of heparanase by albumin and advanced glycation end products in proximal tubular cells. Biochim Biophys Acta 2011, 1813(8):1475-1482. 10.1016/j.bbamcr.2011.05.004, 21600934.
14. Gil N, Goldberg R, Neuman T, Garsen M, Zcharia E, Rubinstein AM, van Kuppevelt T, Meirovitz A, Pisano C, Li JP, van der Vlag J, Vlodavsky I, Elkin M. Heparanase is essential for the development of diabetic nephropathy in mice. Diabetes 2012, 61(1):208-216. 10.2337/db11-1024, 3237641, 22106160.
15. Rops AL, van den Hoven MJ, Veldman BA, Salemink S, Vervoort G, Elving LD, Aten J, Wetzels JF, van der Vlag J, Berden JH. Urinary heparanase activity in patients with Type 1 and Type 2 diabetes. Nephrol Dial Transplant 2012, 27(7):2853-2861. 10.1093/ndt/gfr732, 22187315.
16. Chen S, Fang Z, Zhu Z, Deng A, Liu J, Zhang C. Protective effect of sulodexide on podocyte injury in adriamycin nephropathy rats. J Huazhong Univ Sci Technol Med Sci 2009, 29(6):715-719. 10.1007/s11596-009-0608-0, 20037813.
17. Lewis EJ, Xu X. Abnormal glomerular permeability characteristics in diabetic nephropathy: implications for the therapeutic use of low-molecular weight heparin. Diabetes Care 2008, 31(Suppl 2):S202-S207.
18. Wijnhoven TJ, Lensen JF, Rops AL, McCarthy KJ, van der Vlag J, Berden JH, van den Heuvel LP, van Kuppevelt TH. Anti-proteinuric effects of glycosaminoglycan-based drugs. Curr Opin Mol Ther 2007, 9(4):364-377.
19. Weiss R, Niecestro R, Raz I. The role of sulodexide in the treatment of diabetic nephropathy. Drugs 2007, 67(18):2681-2696. 10.2165/00003495-200767180-00004, 18062718.
20. Abaterusso C, Gambaro G. The role of glycosaminoglycans and sulodexide in the treatment of diabetic nephropathy. Treat Endocrinol 2006, 5(4):211-222. 10.2165/00024677-200605040-00002, 16879000.
21. Pletinck A, Van Landschoot M, Steppan S, Laukens D, Passlick-Deetjen J, Vanholder R, Van Biesen W. Oral supplementation with sulodexide inhibits neo-angiogenesis in a rat model of peritoneal perfusion. Nephrol Dial Transplant 2012, 27(2):548-556. 10.1093/ndt/gfr370, 21750165.
22. Onisto M, Slongo ML, Gregnanin L, Gastaldi T, Carli M, Rosolen A. Expression and activity of vascular endothelial growth factor and metalloproteinases in alveolar and embryonal rhabdomyosarcoma cell lines. Int J Oncol 2005, 27(3):791-798.
23. Liang CC, Park AY, Guan JL. In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc 2007, 2(2):329-333. 10.1038/nprot.2007.30, 17406593.
24. van den Hoven MJ, Rops AL, Bakker MA, Aten J, Rutjes N, Roestenberg P, Goldschmeding R, Zcharia E, Vlodavsky I, van der Vlag J, Berden JH. Increased expression of heparanase in overt diabetic nephropathy. Kidney Int 2006, 70(12):2100-2108.
25. Nasser NJ. Heparanase involvement in physiology and disease. Cell Mol Life Sci 2008, 65(11):1706-1715. 10.1007/s00018-008-7584-6, 18425416.
26. Lauver DA, Lucchesi BR. Sulodexide: a renewed interest in this glycosaminoglycan. Cardiovasc Drug Rev 2006, 24(3-4):214-226.
27. Naggi A, Casu B, Perez M, Torri G, Cassinelli G, Penco S, Pisano C, Giannini G, Ishai-Michaeli R, Vlodavsky I. Modulation of the heparanase-inhibiting activity of heparin through selective desulfation, graded N-acetylation, and glycol splitting. J Biol Chem 2005, 280(13):12103-12113.